Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 802903, 5 pages
http://dx.doi.org/10.1155/2015/802903
Research Article

Metabolic Interaction of the Active Constituents of Coptis chinensis in Human Liver Microsomes

Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received 7 September 2014; Revised 24 November 2014; Accepted 24 December 2014

Academic Editor: Yuping Tang

Copyright © 2015 Songcan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Chinese Pharmacopoeia Commission, Pharmacopoeia of the People's Republic of China, vol. 1, Chinese Medicinal Science and Technology Press, Beijing, China, 2010, (Chinese).
  2. J. Sun, J.-S. Ma, J. Jin et al., “Qualitative and quantitative determination of the main components of Huanglianjiedu decoction by HPLC-UV/MS,” Yaoxue Xuebao, vol. 41, no. 4, pp. 380–384, 2006. View at Google Scholar · View at Scopus
  3. U. K. Choi, M. H. Kim, and N. H. Lee, “Optimization of antibacterial activity by gold-thread (Coptidis Rhizoma Franch) against Streptococcus mutans using evolutionary operation-factorial design technique,” Journal of Microbiology and Biotechnology, vol. 17, no. 11, pp. 1880–1884, 2007. View at Google Scholar · View at Scopus
  4. Y. F. Zhang, X. Y. Li, D. J. Zou et al., “Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 7, pp. 2559–2565, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. L. Yuan, D. Tu, X. Ye, and J. Wu, “Hypoglycemic and hypocholesterolemic effects of Coptis chinensis franch inflorescence,” Plant Foods for Human Nutrition, vol. 61, no. 3, pp. 139–144, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. N. Pinto and M. E. Dolan, “Clinically relevant genetic variations in drug metabolizing enzymes,” Current Drug Metabolism, vol. 12, no. 5, pp. 487–497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Guo, F. Li, X. Ma, X. Cheng, H. Zhou, and C. D. Klaassen, “CYP2D plays a major role in berberine metabolism in liver of mice and humans,” Xenobiotica, vol. 41, no. 11, pp. 996–1005, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. Y. Zhang, W. Wu, F. Han, and Y. Chen, “LC/MS/MS for identification of in vivo and in vitro metabolites of jatrorrhizine,” Biomedical Chromatography, vol. 22, no. 12, pp. 1360–1367, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. R. Shi, H. Zhou, B. Ma et al., “Pharmacokinetics and metabolism of jatrorrhizine, a gastric prokinetic drug candidate,” Biopharmaceutics & Drug Disposition, vol. 33, no. 3, pp. 135–145, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. Y.-L. Han, H.-L. Yu, D. Li et al., “In vitro inhibition of huanglian [Rhizoma coptidis (L.)] and its six active alkaloids on six cytochrome P450 isoforms in human liver microsomes,” Phytotherapy Research, vol. 25, no. 11, pp. 1660–1665, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. Y.-T. Liu, H.-P. Hao, H.-G. Xie et al., “Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats,” Drug Metabolism and Disposition, vol. 38, no. 10, pp. 1779–1784, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. W. Hua, L. Ding, Y. Chen, B. Gong, J. He, and G. Xu, “Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 44, no. 4, pp. 931–937, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. FDA, “Guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling,” http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf.
  14. F. Qiu, R. Zhang, J. Sun et al., “Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes,” Drug Metabolism and Disposition, vol. 36, no. 7, pp. 1308–1314, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. F. Zuo, N. Nakamura, T. Akao, and M. Hattori, “Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry,” Drug Metabolism & Disposition, vol. 34, no. 12, pp. 2064–2072, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. Y. T. Liu, H. P. Hao, H. G. Xie, H. Lv, C. X. Liu, and G. J. Wang, “Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats,” Journal of Pharmaceutical Sciences, vol. 98, no. 11, pp. 4391–4401, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. M. Zhu, F. M. Han, H. X. Chen, Z. H. Peng, and Y. Chen, “Identification of palmatine and its metabolites in rat urine by liquid chromatography/tandem mass spectrometry,” Rapid Communications in Mass Spectrometry, vol. 21, no. 13, pp. 2019–2022, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. M.-P. Shen, Q. Sun, and H. Wang, “Studies on the intravenous pharmacokinetics and oral absorption of berberine HCl in beagle dogs,” Chinese Pharmacological Bulletin, vol. 9, no. 1, pp. 64–67, 1993. View at Google Scholar · View at Scopus
  19. C. Yu, H. Zhang, J. Pan et al., “Determination and preliminary studies of metabolism of berberine in human urine after oral administration,” The Chinese Journal of Clinical Pharmacology, vol. 16, pp. 36–39, 2000. View at Google Scholar